Clinical phase I/II trial to investigate neoadjuvant intensity-modulated short term radiation therapy (5 × 5 gy) and intraoperative radiation therapy (15 gy) in patients with primarily resectable pancreatic cancer - NEOPANC
Authors:
- Falk RoederFRFalk Roeder
- Carmen TimkeCTCarmen Timke
- Ladan Saleh-EbrahimiLSLadan Saleh-Ebrahimi
- Lutz SchneiderLSLutz Schneider
- Thilo HackertThilo Hackert
- Werner HartwigWHWerner Hartwig
- Annette Kopp-SchneiderAKAnnette Kopp-Schneider
- Frank W HensleyFHFrank W Hensley
- Markus W BuechlerMBMarkus W Buechler
- Juergen DebusJDJuergen Debus
- Peter E HuberPHPeter E Huber
- Jens WernerJWJens Werner
Open Access
- 23 March 2012
- journal article
- Published by Springer Nature in BMC Cancer
- Vol. 12 (1) , 112
Abstract
The current standard treatment, at least in Europe, for patients with primarily resectable tumors, consists of surgery followed by adjuvant chemotherapy. But even in this prognostic favourable group, long term survival is disappointing because of high local and distant failure rates. Postoperative chemoradiation has shown improved local control and overalls survival compared to surgery alone but the value of additional radiation has been questioned in case of adjuvant chemotherapy. However, there remains a strong rationale for the addition of radiation therapy considering the high rates of microscopically incomplete resections after surgery. As postoperative administration of radiation therapy has some general disadvantages, neoadjuvant and intraoperative approaches theoretically offer benefits in terms of dose escalation, reduction of toxicity and patients comfort especially if hypofractionated regimens with highly conformal techniques like intensity-modulated radiation therapy are considered.Keywords
This publication has 33 references indexed in Scilit:
- Adjuvant 5-fluorouracil and folinic acid vs observation for pancreatic cancer: composite data from the ESPAC-1 and -3(v1) trialsBritish Journal of Cancer, 2009
- Chirurgie des PankreaskarzinomsZeitschrift für Gastroenterologie, 2008
- Resection margins and R1 rates in pancreatic cancer – are we there yet?Histopathology, 2007
- S3-Leitlinie „Exokrines Pankreaskarzinom” 2007Zeitschrift für Gastroenterologie, 2007
- Long-term results of a randomized trial comparing preoperative short-course radiotherapy with preoperative conventionally fractionated chemoradiation for rectal cancerBritish Journal of Surgery, 2006
- Neoadjuvant chemoradiation in patients with pancreatic adenocarcinomaHPB, 2006
- Neoadjuvant therapy for pancreatic cancer: the Duke experienceSurgical Oncology Clinics of North America, 2004
- Development of a disease specific quality of life (QoL) questionnaire module to supplement the EORTC core cancer QoL questionnaire, the QLQ-C30 in patients with pancreatic cancerEuropean Journal of Cancer, 1999
- The European Organization for Research and Treatment of Cancer QLQ-C30: A Quality-of-Life Instrument for Use in International Clinical Trials in OncologyJNCI: Journal of the National Cancer Institute, 1993
- Resection Margins in Carcinoma of the Head of the PancreasAnnals of Surgery, 1993